Mobidiag secures $28M loan to expedite diagnostics development | Roche Diagnostics announces launch of molecular TB test | PET study sheds light on possible suicidal ideation biomarker in PTSD
May 15, 2019
AACC SmartBrief
Business Perspective
Mobidiag secures $28M loan to expedite diagnostics development
Mobidiag secured a four-year loan worth about $28 million from the European Investment Bank. The company said it will use the money for validation and commercialization of new molecular diagnostic tests running on the firm's Amplidiag and Novodiag platforms.
European Biotechnology (Germany) (5/15) 
LinkedIn Twitter Facebook Email
Roche Diagnostics announces launch of molecular TB test
Roche Diagnostics has commercially released its Cobas MTB-RIF/INH test for antibiotic resistance detection in tuberculosis DNA. The product comes as part of the mycobacterium test menu that runs on the company's automated Cobas 6800/8800 systems.
Seeking Alpha (5/14) 
LinkedIn Twitter Facebook Email
BD BACTEC platelet media
From FDA-cleared platelet testing media to advanced informatics, BD now offers an integrated, culture-based solution to help meet the platelet quality control testing requirements of clinical microbiology laboratories. Click here to learn more.
Science Briefs
PET study sheds light on possible suicidal ideation biomarker in PTSD
Researchers who used PET found that individuals with post-traumatic stress disorder and suicidal thoughts had significantly elevated metabotropic glutamatergic receptor 5 availability across five key brain regions and had a positive correlation between total Profile of Mood States scores and mGluR5 availability, but the association wasn't observed among those with PTSD who did not have suicidal thoughts. The findings, published in the Proceedings of the National Academy of Sciences, suggest that mGluR5 downregulation might curb PTSD symptomology, but more studies are needed, said researcher Dr. Irina Esterlis.
Medscape (free registration) (5/13) 
LinkedIn Twitter Facebook Email
Research finds no link between prediabetes, impaired kidney function
A Portuguese study in The Journal of Clinical Endocrinology & Metabolism showed no association between prediabetes and worsening kidney function or incident albuminuria in the short term, with similar rates seen among those with impaired fasting glucose and normoglycemia. Findings were based on an analysis of data from the SPRINT trial involving 9,361 participants without diabetes at baseline, mean age of 68.
Healio (free registration)/Endocrine Today (5/13) 
LinkedIn Twitter Facebook Email
Research links diabetes to higher cancer metastasis risk
People with diabetes may be at an increased risk of cancer metastasis due to elevated blood glucose levels that could lead to glycation, which in turn "promotes the rate of metastasizing," lead study author Young Joon Suh wrote in the journal Integrative Biology. Researchers examined how breast cancer tumor cells survived in environments with varying glycation levels and found that cells in environments with high glycation had increased motility and were able to move farther away from the original site.
Medical News Today (5/8) 
LinkedIn Twitter Facebook Email
Tech Briefs
FDA gives breakthrough status to Grail's multicancer blood test
The FDA has given Illumina spinout Grail breakthrough device designation for its early detection test that can spot multiple cancer types from a single blood sample. The sequencing test is being evaluated in a 37-site US study involving around 100,000 women.
PMLive (UK) (5/14) 
LinkedIn Twitter Facebook Email
Business/Corporate Briefs
Brazil approves Chembio's dengue test
Chembio Diagnostic Systems' point-of-care test for dengue was granted approval by Brazilian regulators. The DPP Dengue System requires a drop of blood from the fingertip and can generate results within 15 minutes.
Innovate Long Island (N.Y.) (5/8) 
LinkedIn Twitter Facebook Email
NanoString generates $27.7M in Q1 revenue
NanoString Technologies reported revenue of $27.7 million during its first quarter. The firm also posted a loss of $21.9 million during the period.
Yahoo/The Associated Press (5/9) 
LinkedIn Twitter Facebook Email
Accelerate Diagnostics reports $1.8M in Q1 revenue
Accelerate Diagnostics generated $1.8 million in revenue during its first quarter, while posting a loss of $21.7 million.
Yahoo/The Associated Press (5/9) 
LinkedIn Twitter Facebook Email
The 71st AACC Annual Scientific Meeting & Clinical Lab Expo
Join your community for five days of scientific education, problem-solving and networking in Anaheim, CA. August 4-8, 2019.
LinkedIn Twitter Facebook Email
Webinar: Breaking the Bottleneck: Implementation of a Middleware Solution for Automated Mass Spectrometry Data Review
Dr. Alec Saitman will provide insight into an auto-data review program developed by Providence Regional Laboratories. This program has unique advantage of providing dynamic rule flags against patient samples using calibrator averages of important data elements. May 29, 2019
LinkedIn Twitter Facebook Email
Learn more about AACC:
AACC Homepage | AACC Membership | Annual Meeting
Clinical Laboratory News | Clinical Chemistry | JALM
Sign Up
SmartBrief offers 200+ newsletters
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Contributing Editor  -  Genna Rollins
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  April Hollis
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2019 SmartBrief, Inc.®
Privacy Policy (updated May 25, 2018) |  Legal Information